1
|
Hamada Y, Quartagno M, Law I, Malik F, Bonsu FA, Adetifa IM, Adusi-Poku Y, D'Alessandro U, Bashorun AO, Begum V, Lolong DB, Boldoo T, Dlamini T, Donkor S, Dwihardiani B, Egwaga S, Farid MN, Celina G.Garfin AM, Mae G Gaviola D, Husain MM, Ismail F, Kaggwa M, Kamara DV, Kasozi S, Kaswaswa K, Kirenga B, Klinkenberg E, Kondo Z, Lawanson A, Macheque D, Manhiça I, Maama-Maime LB, Mfinanga S, Moyo S, Mpunga J, Mthiyane T, Mustikawati DE, Mvusi L, Nguyen HB, Nguyen HV, Pangaribuan L, Patrobas P, Rahman M, Rahman M, Rahman MS, Raleting T, Riono P, Ruswa N, Rutebemberwa E, Rwabinumi MF, Senkoro M, Sharif AR, Sikhondze W, Sismanidis C, Sovd T, Stavia T, Sultana S, Suriani O, Thomas AM, Tobing K, Van der Walt M, Walusimbi S, Zaman MM, Floyd K, Copas A, Abubakar I, Rangaka MX. Association of diabetes, smoking, and alcohol use with subclinical-to-symptomatic spectrum of tuberculosis in 16 countries: an individual participant data meta-analysis of national tuberculosis prevalence surveys. EClinicalMedicine 2023; 63:102191. [PMID: 37680950 PMCID: PMC10480554 DOI: 10.1016/j.eclinm.2023.102191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 07/24/2023] [Accepted: 08/16/2023] [Indexed: 09/09/2023] Open
Abstract
Background Non-communicable diseases (NCDs) and NCD risk factors, such as smoking, increase the risk for tuberculosis (TB). Data are scarce on the risk of prevalent TB associated with these factors in the context of population-wide systematic screening and on the association between NCDs and NCD risk factors with different manifestations of TB, where ∼50% being asymptomatic but bacteriologically positive (subclinical). We did an individual participant data (IPD) meta-analysis of national and sub-national TB prevalence surveys to synthesise the evidence on the risk of symptomatic and subclinical TB in people with NCDs or risk factors, which could help countries to plan screening activities. Methods In this systematic review and IPD meta-analysis, we identified eligible prevalence surveys in low-income and middle-income countries that reported at least one NCD (e.g., diabetes) or NCD risk factor (e.g., smoking, alcohol use) through the archive maintained by the World Health Organization and by searching in Medline and Embase from January 1, 2000 to August 10, 2021. The search was updated on March 23, 2023. We performed a one-stage meta-analysis using multivariable multinomial models. We estimated the proportion of and the odds ratio for subclinical and symptomatic TB compared to people without TB for current smoking, alcohol use, and self-reported diabetes, adjusted for age and gender. Subclinical TB was defined as microbiologically confirmed TB without symptoms of current cough, fever, night sweats, or weight loss and symptomatic TB with at least one of these symptoms. We assessed heterogeneity using forest plots and I2 statistic. Missing variables were imputed through multi-level multiple imputation. This study is registered with PROSPERO (CRD42021272679). Findings We obtained IPD from 16 national surveys out of 21 national and five sub-national surveys identified (five in Asia and 11 in Africa, N = 740,815). Across surveys, 15.1%-56.7% of TB were subclinical (median: 38.1%). In the multivariable model, current smoking was associated with both subclinical (OR 1.67, 95% CI 1.27-2.40) and symptomatic TB (OR 1.49, 95% CI 1.34-1.66). Self-reported diabetes was associated with symptomatic TB (OR 1.67, 95% CI 1.17-2.40) but not with subclinical TB (OR 0.92, 95% CI 0.55-1.55). For alcohol drinking ≥ twice per week vs no alcohol drinking, the estimates were imprecise (OR 1.59, 95% CI 0.70-3.62) for subclinical TB and OR 1.43, 95% CI 0.59-3.46 for symptomatic TB). For the association between current smoking and symptomatic TB, I2 was high (76.5% (95% CI 62.0-85.4), while the direction of the point estimates was consistent except for three surveys with wide CIs. Interpretation Our findings suggest that current smokers are more likely to have both symptomatic and subclinical TB. These individuals can, therefore, be prioritised for intensified screening, such as the use of chest X-ray in the context of community-based screening. People with self-reported diabetes are also more likely to have symptomatic TB, but the association is unclear for subclinical TB. Funding None.
Collapse
Affiliation(s)
- Yohhei Hamada
- Institute for Global Health, University College London, United Kingdom
| | - Matteo Quartagno
- MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, United Kingdom
| | - Irwin Law
- Global Tuberculosis Programme, World Health Organization, Switzerland
| | - Farihah Malik
- UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom
| | | | - Ifedayo M.O. Adetifa
- Disease Control and Elimination Theme, Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Gambia
- Department of Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, United Kingdom
| | - Yaw Adusi-Poku
- National Tuberculosis Programme, Ghana Health Service, Ghana
| | - Umberto D'Alessandro
- Disease Control and Elimination Theme, Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Gambia
| | - Adedapo Olufemi Bashorun
- Disease Control and Elimination Theme, Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Gambia
| | | | | | - Tsolmon Boldoo
- Tuberculosis Surveillance and Research Department, National Center for Communicable Disease, Mongolia
| | - Themba Dlamini
- Eswatini National Tuberculosis Program, Ministry of Health, Eswatini
| | - Simon Donkor
- Disease Control and Elimination Theme, Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Gambia
| | - Bintari Dwihardiani
- Center for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Indonesia
| | - Saidi Egwaga
- Tuberculosis and Leprosy Programme, Ministry of Health and Social Welfare, United Republic of Tanzania
| | | | | | | | | | - Farzana Ismail
- Centre for Tuberculosis, National Institute for Communicable Diseases, A Division of the National Health Laboratory Services, South Africa
- Department of Medical Microbiology, University of Pretoria, South Africa
| | - Mugagga Kaggwa
- World Health Organization, Country Office for Uganda, Uganda
| | - Deus V. Kamara
- Tuberculosis and Leprosy Programme, Ministry of Health and Social Welfare, United Republic of Tanzania
| | - Samuel Kasozi
- National Tuberculosis Control Programme, Ministry of Health, Uganda
| | | | | | - Eveline Klinkenberg
- Department of Global Health, Amsterdam University Medical Center, Netherlands
| | - Zuweina Kondo
- Tuberculosis and Leprosy Programme, Ministry of Health and Social Welfare, United Republic of Tanzania
| | - Adebola Lawanson
- National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health, Nigeria
| | - David Macheque
- National Tuberculosis Program, Ministry of Health, Mozambique
| | - Ivan Manhiça
- National Tuberculosis Program, Ministry of Health, Mozambique
| | | | - Sayoki Mfinanga
- Institute for Global Health, University College London, United Kingdom
- National Institute for Medical Research, Muhimbili Medical Research Centre, United Republic of Tanzania
- Liverpool School of Tropical Medicine, United Kingdom
- Alliance for Africa Health and Research, United Republic of Tanzania
| | - Sizulu Moyo
- Human Sciences Research Council, South Africa
- School of Public Health and Family Medicine, University of Cape Town, South Africa
| | - James Mpunga
- National Tuberculosis Programme, Ministry of Health, Malawi
| | | | | | | | | | | | | | - Philip Patrobas
- World Health Organization, Country Office for Nigeria, Nigeria
| | - Mahmudur Rahman
- Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh
| | - Mahbubur Rahman
- Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh
| | | | | | | | | | - Elizeus Rutebemberwa
- Department of Health Policy, Planning and Management, Makerere University School of Public Health, Uganda
| | | | - Mbazi Senkoro
- National Institute for Medical Research, Muhimbili Medical Research Centre, United Republic of Tanzania
| | | | - Welile Sikhondze
- Eswatini National Tuberculosis Program, Ministry of Health, Eswatini
| | | | | | | | - Sabera Sultana
- World Health Organization, Country Office for Bangladesh, Bangladesh
| | | | | | | | | | | | | | - Katherine Floyd
- Global Tuberculosis Programme, World Health Organization, Switzerland
| | - Andrew Copas
- Institute for Global Health, University College London, United Kingdom
| | - Ibrahim Abubakar
- Institute for Global Health, University College London, United Kingdom
| | - Molebogeng X. Rangaka
- Institute for Global Health, University College London, United Kingdom
- Division of Epidemiology and Biostatistics & CIDRI-AFRICA, University of Cape Town, South Africa
| |
Collapse
|
3
|
Abstract
Background: Africa has the lowest childhood vaccination coverage worldwide. If the full benefits of childhood vaccination programmes are to be enjoyed in sub-Saharan Africa, all countries need to improve on vaccine delivery to achieve and sustain high coverage. In this paper, we review trends in vaccination coverage, dropouts between vaccine doses and explored the country-specific predictors of complete vaccination in West Africa. Methods: We utilized datasets from the Demographic and Health Surveys Program, available for Benin, Burkina Faso, The Gambia, Ghana, Guinea, Cote d'Ivoire, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo, to obtain coverage for Bacillus Calmette-Guerin, polio, measles, and diphtheria, pertussis and tetanus (DPT) vaccines in children aged 12 - 23 months. We also calculated the DPT1-to-DPT3 and DPT1-to-measles dropouts, and proportions of the fully immunised child (FIC). Factors predictive of FIC were explored using Chi-squared tests and multivariable logistic regression. Results: Overall, there was a trend of increasing vaccination coverage. The proportion of FIC varied significantly by country (range 24.1-81.4%, mean 49%). DPT1-to-DPT3 dropout was high (range 5.1% -33.9%, mean 16.3%). Similarly, DPT1-measles dropout exceeded 10% in all but four countries. Although no single risk factor was consistently associated with FIC across these countries, maternal education, delivery in a health facility, possessing a vaccine card and a recent post delivery visit to a health facility were the key predictors of complete vaccination. Conclusions: The low numbers of fully immunised children and high dropout between vaccine doses highlights weaknesses and the need to strengthen the healthcare and routine immunization delivery systems in this region. Country-specific correlates of complete vaccination should be explored further to identify interventions required to increase vaccination coverage. Despite the promise of an increasing trend in vaccination coverage in West African countries, more effort is required to attain and maintain global vaccination coverage targets.
Collapse
Affiliation(s)
- Jacob S. Kazungu
- Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research (Coast), Kilifi, Kenya
- Department of Public Health, Pwani University, Kilifi, Kenya
| | - Ifedayo M.O. Adetifa
- Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research (Coast), Kilifi, Kenya
- Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
- College of Medicine, University of Lagos, Lagos, Nigeria
| |
Collapse
|
4
|
Tientcheu LD, Maertzdorf J, Weiner J, Adetifa IM, Mollenkopf HJ, Sutherland JS, Donkor S, Kampmann B, Kaufmann SHE, Dockrell HM, Ota MO. Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment. Genes Immun 2015; 16:347-55. [PMID: 26043170 PMCID: PMC4515549 DOI: 10.1038/gene.2015.21] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2015] [Revised: 04/15/2015] [Accepted: 04/24/2015] [Indexed: 12/11/2022]
Abstract
The epidemiology of Mycobacterium tuberculosis (Mtb) and M. africanum (Maf) suggest differences in their virulence, but the host immune profile to better understand the pathogenesis of tuberculosis (TB) have not been studied. We compared the transcriptomic and metabolic profiles between Mtb and Maf-infected TB cases to identify host biomarkers associated with lineages-specific pathogenesis and response to anti-TB chemotherapy. Venous blood samples from Mtb- and Maf-infected patients obtained before and after anti-TB treatment were analysed for cell composition, gene expression and metabolic profiles. Prior to treatment, similar transcriptomic profiles were seen in Maf- and Mtb-infected patients. In contrast, post-treatment, over 1600 genes related to immune responses and metabolic diseases were differentially expressed between the groups. Notably, the upstream regulator hepatocyte nuclear factor 4-alpha (HNF4α), which regulated 15% of these genes, was markedly enriched. Serum metabolic profiles were similar in both group pre-treatment, but the decline in pro-inflammatory metabolites post-treatment were most pronounced in Mtb-infected patients. Together, the differences in both peripheral blood transcriptomic and serum metabolic profiles between Maf- and Mtb-infected patients observed over the treatment period, might be indicative of intrinsic host factors related to susceptibility to TB and/or differential efficacy of the standard anti-TB treatment on the two lineages.
Collapse
Affiliation(s)
- L D Tientcheu
- 1] Vaccinology Theme, Medical Research Council Unit, The Gambia, Banjul, The Gambia [2] Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK [3] Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
| | - J Maertzdorf
- Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
| | - J Weiner
- Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
| | - I M Adetifa
- Disease Control and Elimination Theme, Medical Research Council Unit-The Gambia, Fajara, The Gambia
| | - H-J Mollenkopf
- Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
| | - J S Sutherland
- Vaccinology Theme, Medical Research Council Unit, The Gambia, Banjul, The Gambia
| | - S Donkor
- Vaccinology Theme, Medical Research Council Unit, The Gambia, Banjul, The Gambia
| | - B Kampmann
- Vaccinology Theme, Medical Research Council Unit, The Gambia, Banjul, The Gambia
| | - S H E Kaufmann
- Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
| | - H M Dockrell
- Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
| | - M O Ota
- 1] Vaccinology Theme, Medical Research Council Unit, The Gambia, Banjul, The Gambia [2] World Health Organization Regional Office for Africa, Brazzaville, Congo
| |
Collapse
|